Immunohistochemistry (IHC) Market Analysis, Top Companies, New Technology, Demand and Opportunity Analysis
The global immunohistochemistry (IHC) market is witnessing
considerable growth due to increasing geriatric population, increasing
healthcare expenditure and growing awareness about histopathology. Moreover,
growing prevalence of chronic diseases including cancer, cardiovascular
disease, infectious diseases, autoimmune diseases, diabetes mellitus, and
nephrological diseases is supporting the growth of the market. Based on product
type, the kit segment is expected to grow at faster rate during the forecast
period. The increasing adoption of IHC kit across the globe, owing to its ease
of use, availability of ready to use reagents and antibodies, and optimized
sensitivity of the antibody to the antigen, is driving the growth of this
segment.
According to the International Agency for Research on Cancer (IARC), a
specialized cancer agency of WHO that promotes cancer research, as many as 12.7
million new patients were detected with cancer in 2008 globally and the number
is expected to reach 21.4 million by 2030. Further, a total of 8.2 million
deaths took place globally due to cancer in 2012, of which 1.6 million deaths
were due to lung cancer, while 745,000 deaths were due to liver cancer, and
400,000 deaths were a result of oesophageal cancer.
Download Sample of
This Research Report: https://www.psmarketresearch.com/market-analysis/immunohistochemistry-market/report-sample
Geographically, North America has been the largest market for IHC,
owing to increased awareness, established healthcare industry, and easy
accessibility to advanced technologies. The U.S. contributed largest revenue to
the North American as well as global IHC market. The advanced cancer diagnostic
testing and cancer screening is the key growth driving factor for the U.S. IHC
market.
Europe has been the second largest market for IHC, where the market is
driven by the presence of a large pool of cancer patients, increasing
healthcare expenditure and rapidly developing healthcare infrastructure. In
2015, Germany lead the European IHC market and it is also expected to grow at
the fastest rate in Europe, during forecast period. Globally, the IHC market is
expected to witness the fastest growth in Asia-Pacific during the forecast
period. The highest growth in the region is attributed to the increasing
prevalence of chronic diseases, increasing per capita income leading to
improving standard of living, increasing healthcare spending, growing demand
for better quality medical care, and awareness about IHC tests in the region.
Moreover, increasing prevalence of geriatric population and increasing
prevalence of cancer in the region further supports the market growth.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunohistochemistry-market
The key players operating in the global IHC market are F. Hoffmann-LA Roche AG, Danaher
Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck
Millipore, Bio-Rad Laboratories, Inc., Perkinelmer, Inc., Cell Signaling
Technology, Inc., Bio SB and Abcam PLC.
Comments
Post a Comment